Pharma companies directory 2026

    Pharmaceutical Companies in Spain

    Spanish medicines policy is a two-step dance that foreign teams keep underestimating: AEMPS and the Interministerial Pricing Commission speak for the State, then seventeen autonomous communities buy, tender and sometimes delay.

    The Ministry of Health’s 2024 SNS pharmaceutical report put outpatient prescription spending at €13.865 billion, 4.9% above 2023, with generics already 47.4% of packs on those prescriptions. Farmaindustria-linked figures for 2023 had placed the combined hospital-plus-retail market near €23 billion, and hospital lines have been growing faster than the pharmacy counter ever since. What is distinctive is the industrial mix. Barcelona and its hinterland hold Almirall, Esteve, Grifols, Ferrer and Reig Jofre; Madrid holds Rovi and PharmaMar; Navarre’s Cinfa and the Basque Faes Farma complete a domestically owned strip that is stronger in dermatology, plasma, hospital injectables and unbranded generics than in primary-care originator brands. Pfizer and Novartis still lead many specialty value pools. Reference pricing then compresses anything that has a generic or a same-ATC-5 neighbour. BioNixus keeps the companies and institutions below on one sheet because a national price letter without a Catalan, Madrid or Andalusian tender plan is only half a launch.

    Updated September 2026 · Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) — authorised medicines and inspected manufacturers as of September 2026 · 18 named accounts

    Request a proposal for SpainBrowse the 18 companies

    €13.87bn

    SNS outpatient prescription spend in 2024, Ministry of Health (+4.9% vs 2023)

    47.4%

    Generic share of SNS prescription packs in 2024 (24.5% of that spend)

    17

    Autonomous communities that run health services, formularies and hospital tenders

    22,557

    Medicine presentations financed by the SNS at end-2024, 68.4% of those authorised

    Named accounts

    Top pharmaceutical companies in Spain

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) — authorised medicines and inspected manufacturers (as of 2026-09-04).
    #CompanyHQ
    01AlmirallBarcelona
    02EsteveBarcelona
    03GrifolsBarcelona
    04FerrerBarcelona
    05Laboratorios Farmacéuticos RoviMadrid
    06PharmaMarMadrid
    07CinfaHuarte
    08Faes FarmaLeioa
    09Reig JofreBarcelona
    10Laboratorios NormonTres Cantos
    11Kern PharmaTerrassa
    12Pfizer EspañaMadrid
    13Novartis EspañaBarcelona
    14Roche Farma EspañaMadrid
    15Spanish Agency of Medicines and Medical Devices (AEMPS)Madrid
    16Ministerio de Sanidad — pharmaceutical provisionMadrid
    17Servei Català de la Salut (CatSalut)Barcelona
    18CofaresMadrid

    Primary research

    These are the pharmaceutical companies accounts we study in Spain

    Need account-level or SKU-level data for a brand in Spain? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Spain?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top healthcare market research companies in Spain (2026)

    How the market is structured

    National listing, then seventeen buyers: how Spanish medicines move

    AEMPS grants the marketing authorisation, or recognises an EMA decision, and writes the Informe de Posicionamiento Terapéutico that frames clinical value. Price and reimbursement then move to the Comisión Interministerial de Precios de los Medicamentos. Once a product is financed, the sistema de precios de referencia can pull it into a group whose reimbursed price is the lowest cost-per-day in that ATC-5 plus route cluster — a mechanism that has made Spain a hard market for anything that is no longer unique. After that national layer, the 17 comunidades autónomas take over. Catalonia’s CatSalut, Madrid’s SERMAS, Andalusia’s SAS and the Basque Osakidetza run their own commissions, hospital tenders and, in some cases, centralised purchasing. Hospital pharmacy directors sit on those committees and behave as buyers, not as a channel. Community pharmacies remain owner-operated offices supplied by cooperatives such as Cofares and Bidafarma; they dispense the SNS prescription but do not set the financed price. Plasma (Grifols), hospital heparins and biosimilars (Rovi), and oncology from the sea (PharmaMar) give Spain a specialty manufacturing identity that is easy to miss if the brief only lists affiliates.

    Local

    Spanish-owned houses clustered in Catalonia, Madrid, Navarre and the Basque Country — dermatology, plasma, hospital injectables, marine oncology and high-volume generics.

    • Almirall
    • Esteve
    • Grifols
    • Ferrer
    • Laboratorios Farmacéuticos Rovi
    • PharmaMar
    • Cinfa
    • Faes Farma
    • Reig Jofre
    • Laboratorios Normon
    • Kern Pharma

    Multinational

    Originator affiliates whose Spanish value is hospital specialty and vaccines, released only after CIPM pricing and a second round of autonomous-community decisions.

    • Pfizer España
    • Novartis España
    • Roche Farma España

    Regional

    Latin American and wider-Iberian groups (Kern’s Insud parent is the type case) that use a Spanish plant or affiliate to reach SNS tenders and Portuguese spillover.

    Distributors & importers

    AEMPS, the Ministry, CatSalut and the other sixteen health services, plus pharmacy cooperatives that move financed packs to owner-operated offices.

    • Spanish Agency of Medicines and Medical Devices (AEMPS)
    • Ministerio de Sanidad — pharmaceutical provision
    • Servei Català de la Salut (CatSalut)
    • Cofares

    Market structure

    Why the IPT and the autonomous commission are separate research jobs

    The Informe de Posicionamiento Terapéutico is written to be quoted. Regional pharmacists lift sentences from it into commission papers, which is why a fuzzy comparator or an ungenerous place-in-therapy paragraph can stall a brand in Barcelona or Seville even after CIPM has set a price. BioNixus therefore tests IPT language with hospital pharmacists before the document is final, not after.

    Autonomous tenders then add a second clock. A community can wait for a biosimilar, bundle lots across hospitals, or demand an outcome clause the national letter never mentioned. Madrid and Catalonia are not interchangeable, and Andalusia’s scale can move national pack share on its own.

    What is moving

    What is moving the pharmaceutical market in Spain

    Reference-price compression

    Once a molecule or ATC-5 group has a cheaper neighbour, the SNS reimburses the lowest cost-per-day. That is why Cinfa, Normon and Kern take pack share and why originators exit or re-license older lines.

    Seventeen autonomous tenders

    Hospital specialty does not travel on a single national contract. Catalonia, Madrid, Andalusia and the Basque Country each run commissions and lots, so access research is a multi-payer design.

    Plasma and hospital injectables as Spanish specialties

    Grifols on immunoglobulins and Rovi on heparins and fill-finish give domestic capital a hospital role that generic substitution cannot erase, and they set tender norms other suppliers must meet.

    Hospital growth outrunning the pharmacy counter

    Ministry and Farmaindustria series both show hospital lines rising faster than outpatient prescriptions, which pulls budget, IPT scrutiny and regional politics toward oncology, immunology and advanced therapies.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Spain

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Spain:
    • IPT language tests with hospital pharmacists in Madrid and Barcelona, measuring which comparator and place-in-therapy sentences later appear in commission papers.
    • Autonomous-community tender landscaping for immunoglobulins, LMWH and oncology lots across Catalonia, Madrid and Andalusia, including awarded prices where published.
    • Reference-price cluster reconstructions: which INNs lost originator value after Cinfa, Normon or Kern entered the group.
    • Dermatology and hospital-injectable account work on Almirall, Rovi and Ferrer versus affiliate competitors, using purchase records rather than claimed share.

    Healthcare market research in Spain

    Questions

    Frequently Asked Questions

    Which Spanish-owned pharmaceutical companies should a brand team know first?

    Almirall, Esteve, Grifols, Ferrer, Rovi, PharmaMar, Cinfa, Faes Farma, Reig Jofre, Normon and Kern Pharma. They do not form one league: plasma, dermatology and unbranded generics are different businesses that happen to share a passport.

    How does the Spanish reference-price system change a launch?

    When a financed presentation shares an ATC-5 group and route with a cheaper product, the SNS pays the lowest cost-per-day. Late generics can therefore reprice a whole cluster. Unique hospital specialties stay outside that trap until a competitor or biosimilar arrives.

    Do autonomous communities really delay nationally financed medicines?

    They can. Commissions, hospital formularies and tenders are regional. CatSalut, SERMAS and SAS are the three offices most launch teams model explicitly; the other fourteen still move volume.

    Why does Grifols appear on a medicines-company directory?

    Because plasma-derived immunoglobulins, albumin and alpha-1 antitrypsin are hospital medicines bought on autonomous tenders. Treating Grifols as a diagnostics footnote misses a large Spanish hospital P&L.

    How does BioNixus research pharmaceutical companies in Spain?

    By interviewing hospital pharmacy directors and commission members in Madrid and Barcelona, reconstructing CIPM and IPT outcomes, mapping autonomous tender lots for heparins, immunoglobulins and oncology, and auditing pharmacy cooperatives for generic substitution rates.

    Is BioNixus ranking Spanish pharmaceutical firms by sales?

    Sales rank is not the organising principle. A plasma fractionator, a regional health service and a Pamplona generics house sit together because each decides a different slice of Spanish demand.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Spain. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) — authorised medicines and inspected manufacturers, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Spain, not size.

    • Ministerio de Sanidad, Prestación Farmacéutica en el SNS 2024 — €13.865bn outpatient spend, generic pack share 47.4%
    • Farmaindustria / Faus-Moliner pricing chapter on 2023 hospital-plus-retail market structure and the reference-price system
    • AEMPS authorisation and IPT publications; CatSalut and SERMAS procurement notices, 2024–2026
    • BioNixus Spain IPT, autonomous-tender and hospital-pharmacy fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Spain?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Spain?

    Primary research, market access & HEOR. Proposals within 48 hours.